Fort Washington Investment Advisors Inc. OH Lowers Holdings in AbbVie Inc. $ABBV

Fort Washington Investment Advisors Inc. OH lowered its position in AbbVie Inc. (NYSE:ABBV) by 11.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 196,513 shares of the company’s stock after selling 26,627 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in AbbVie were worth $45,501,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Marshall & Sullivan Inc. WA bought a new position in shares of AbbVie during the 2nd quarter worth $25,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the second quarter valued at about $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the second quarter worth about $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the second quarter worth about $36,000. Finally, Bear Mountain Capital Inc. grew its holdings in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Trading Up 0.4%

NYSE ABBV opened at $230.95 on Tuesday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a 50 day moving average price of $226.70 and a 200 day moving average price of $212.99. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The firm has a market cap of $408.18 billion, a PE ratio of 174.96, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the firm earned $3.00 earnings per share. AbbVie’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Analysts Set New Price Targets

ABBV has been the subject of several recent research reports. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Piper Sandler reiterated an “overweight” rating and set a $289.00 price objective (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research note on Tuesday, November 4th. BMO Capital Markets upped their target price on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Finally, Raymond James Financial set a $256.00 target price on AbbVie in a research report on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.